The Catalyst Issue 10 | Spring 2011 | Page 19

EYE A new wave of technology and additional expertise are giving radiation oncologists more tools to fight tumors OF THE STORM Each year, several thousand cancer patients receive radiation therapy as part of their care, and that number continues to grow. Radiation oncologists work with medical oncologists, surgeons, and other caregivers in designing radiation therapy for a cancer patient’s treatment plan. T he Scott & White Cancer Institute and the Department of Radiation Oncology are meeting patients’ needs, by welcoming a new leader and introducing new therapies to help patients in Central Texas. Subhakar Mutyala, MD, joins Scott & White Cancer Institute as chairman of the Radiation Oncology Department, coming from Montefiore Medical Center in New York. He has previously worked at the DanaFarber Cancer Institute in Boston, Massachusetts, and at the Sylvester Cancer Center in Miami, Florida. Dr. Mutyala sees this as a homecoming, because he graduated from Texas A&M Medical School and has family throughout Central Texas, including in Temple and Waco. “We must improve the practice of radiation oncology as the Scott & White Cancer Institute moves forward,” says Dr. Mutyala, referring to the Cancer Institute’s increasing stature as a unique presence in the national fight against cancer. “Our goal is to offer the highest-quality of care for the population of Central Texas.” Radiation therapy is currently used to treat patients with cancer and noncancerous tumors. Seventy percent of cancer patients will need radiation therapy as part of their treatment, including those who have cancers of the lung, breast, prostate, skin and several other locations. Its application is growing as advanced technology has allowed radiation therapy to be used in areas where radiation was previously viewed as too difficult or too dangerous a therapy. Using 3-D imaging and other sophisticated techniques, radiation oncologists can target the radiation to the tumor and decrease the dose to the patient’s normal tissues and decrease side effects. Because of the www.sw.org | Spring 11 THE CATALYST 19